Axsome Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Axsome Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue385.69270.6050.040.000.000.000.00
Cost of Revenue33.3026.075.200.000.000.000.00
Gross Profit352.39244.5444.840.000.000.000.00
Operating Expenses
Research & Development187.0897.9457.9558.0670.1953.6523.50
Selling, General & Administrative411.36323.12159.2566.6528.9013.609.35
Operating Expenses632.95427.44221.34124.7199.0967.2532.63
Operating Income-280.56-182.91-179.80-124.71-99.09-67.25-32.63
Other Income/Expense
Interest Income0.000.000.000.000.000.000.00
Interest Expense6.576.457.345.70-2.570.001.13
Other Income/Expense-6.57-48.92-3.305.703.811.242.79
Income
Income Before Tax-287.13-238.28-187.13-130.40-102.90-68.48-30.97
Income Tax Expense0.090.960.000.000.000.000.00
Net Income-287.22-239.24-187.13-130.40-102.90-68.35-30.97
Net Income - Continuous Operations-287.22-239.24-187.13-130.400.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-272.60-224.99-175.40-124.63-99.06-66.43-29.79
EBIT-308.71-231.83-179.80-124.71-99.09-67.12-29.84
Depreciation & Amortization7.966.384.140.080.020.000.00
Earnings Per Share
Basic EPS-6.00-5.00-5.00-3.00-3.00-2.00-1.00
Diluted EPS-6.00-5.00-5.00-3.00-3.00-2.00-1.00
Basic Shares Outstanding47.9145.4340.6637.6237.2134.0226.88
Diluted Shares Outstanding47.9145.4340.6637.6237.2134.0226.88